BiotechTube
Indivior PLC

Indivior PLC

INDV
United States

Indivior PLC is a leader in addiction medicine, dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. The company's mission centers on delivering life-changing medicines and digital therapeutics to patients with substance use disorders and co-occurring mental illnesses. Its commercial success is anchored by SUBOXONE® film, and it is strategically expanding its portfolio with novel long-acting injectables like SUBLOCADE® and PERSERIS®, and exploring next-generation treatments. Indivior operates as a public company, navigating a complex regulatory and competitive landscape while addressing one of society's most pressing public health challenges.

indivior.com

INDV · Stock Price

USD 30.26+20.46 (+208.78%)
Market Cap: $3.8B

Historical price data

Market Cap: $3.8BPipeline: 2 drugs (2 Phase 3)Employees: 800-1000HQ: United States

AI Company Overview

Indivior PLC is a leader in addiction medicine, dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. The company's mission centers on delivering life-changing medicines and digital therapeutics to patients with substance use disorders and co-occurring mental illnesses. Its commercial success is anchored by SUBOXONE® film, and it is strategically expanding its portfolio with novel long-acting injectables like SUBLOCADE® and PERSERIS®, and exploring next-generation treatments. Indivior operates as a public company, navigating a complex regulatory and competitive landscape while addressing one of society's most pressing public health challenges.

Substance Use DisordersOpioid Use DisorderSchizophreniaMental Illness

Technology Platform

Expertise in advanced drug delivery systems, including sublingual film and polymer-based long-acting injectable (LAI) formulations for sustained release, combined with a digital therapeutics platform for holistic treatment support.

Pipeline

2
2 drugs in pipeline2 in Phase 3
DrugIndicationStageWatch
SUBLOCADEOpioid Use DisorderPhase 3
SUBLOCADEOpioid Use DisorderPhase 3

Funding History

1
IPOUndisclosed

FDA Approved Drugs

4
OPVEENDAMay 22, 2023
PERSERIS KITNDAJul 27, 2018
SUBLOCADENDANov 30, 2017

Opportunities

Significant growth opportunity lies in increasing market penetration of SUBLOCADE®, its monthly injectable for OUD, in a vast and undertreated patient population.
Further opportunities exist in expanding the use of its digital therapeutics as adjuncts to pharmacotherapy and exploring lifecycle management or new indications for its existing assets.
Geographic expansion outside the core U.S.
market presents a longer-term opportunity.

Risk Factors

Major risks include rapid revenue erosion from generic competition to SUBOXONE® film, intense competition from other branded long-acting injectables, ongoing legal and regulatory scrutiny from past activities, and execution risks associated with the commercial launch and adoption of its newer products.

Competitive Landscape

Indivior faces intense competition from generic buprenorphine products and branded competitors like Alkermes' VIVITROL® and, crucially, Braeburn/Camurus's BRIXADI™, a direct competitor to SUBLOCADE®. Its differentiation is based on its first-mover advantage in film and depot formulations, strong commercial infrastructure, and integrated treatment approach combining medicine and digital support.

Company Timeline

2014IPO

Initial Public Offering

2017FDA Approval

FDA Approval: SUBLOCADE

2018FDA Approval

FDA Approval: PERSERIS KIT

2023FDA Approval

FDA Approval: OPVEE

More companies in United States →